Literature DB >> 25717205

The role of subcutaneous ketorolac for pain management.

Mary E Vacha1, Wennie Huang2, Jennifer Mando-Vandrick2.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2015        PMID: 25717205      PMCID: PMC4336012          DOI: 10.1310/hpj5002-108

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  13 in total

1.  Intermittent subcutaneous opioids for the management of cancer pain.

Authors:  Henrique A Parsons; Abdul Shukkoor; Hue Quan; Marvin O Delgado-Guay; J Lynn Palmer; Robin Fainsinger; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-12       Impact factor: 2.947

2.  Ketorolac: continuous subcutaneous infusion for cancer pain.

Authors:  A Hughes; A Wilcock; R Corcoran
Journal:  J Pain Symptom Manage       Date:  1997-06       Impact factor: 3.612

Review 3.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

4.  Effect of short-term ketorolac infusion on recovery following laparoscopic day surgery.

Authors:  L Campbell; J Plummer; H Owen; A Czuchwicki; A Ilsley
Journal:  Anaesth Intensive Care       Date:  2000-12       Impact factor: 1.669

5.  Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.

Authors:  F De Conno; E Zecca; C Martini; C Ripamonti; A Caraceni; L Saita
Journal:  J Pain Symptom Manage       Date:  1994-02       Impact factor: 3.612

6.  Pain therapy.

Authors:  Carla Ripamonti; Elena Bandieri
Journal:  Crit Rev Oncol Hematol       Date:  2009-02-01       Impact factor: 6.312

7.  Subcutaneous ketorolac--a new development in pain control.

Authors:  N Blackwell; L Bangham; M Hughes; D Melzack; I Trotman
Journal:  Palliat Med       Date:  1993       Impact factor: 4.762

8.  Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain.

Authors:  K G Myers; I F Trotman
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

9.  Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study.

Authors:  B L Strom; J A Berlin; J L Kinman; P W Spitz; S Hennessy; H Feldman; S Kimmel; J L Carson
Journal:  JAMA       Date:  1996-02-07       Impact factor: 56.272

10.  Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report.

Authors:  C Ripamonti; C Ticozzi; E Zecca; C H Rodriguez; F De Conno
Journal:  Tumori       Date:  1996 Jul-Aug
View more
  1 in total

1.  Efficacy of continuous in-wound infusion of levobupivacaine and ketorolac for post-caesarean section analgesia: a prospective, randomised, double-blind, placebo-controlled trial.

Authors:  Jozica Wagner-Kovacec; Petra Povalej-Brzan; Dusan Mekis
Journal:  BMC Anesthesiol       Date:  2018-11-10       Impact factor: 2.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.